Combination Therapy With BRAF and MEK Inhibitors for Melanoma: Latest Evidence and Place in Therapy

Therapeutic Advances in Medical Oncology - United States
doi 10.1177/1758834015616934
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

SAGE Publications

Related search

Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma

Cancers
Cancer ResearchOncology
2019English

Dupilumab in Atopic Dermatitis: Rationale, Latest Evidence and Place in Therapy

Therapeutic Advances in Chronic Disease
Medicine
2018English

Tildrakizumab in the Treatment of Psoriasis: Latest Evidence and Place in Therapy

Therapeutic Advances in Chronic Disease
Medicine
2019English

Inhibitors of Pan-Pi3k Signaling Synergize With BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth

Frontiers in Oncology
Cancer ResearchOncology
2015English

Beyond BRAF: Where Next for Melanoma Therapy?

British Journal of Cancer
Cancer ResearchOncology
2014English

Why Do We Need a New BRAF-MEK Inhibitor Combination in Melanoma?

Oncology in Clinical Practice
Oncology
2019English

Comparison of Responses of Human Melanoma Cell Lines to MEK and BRAF Inhibitors

Frontiers in Genetics
GeneticsMolecular Medicine
2013English

Optimizing Combination Dabrafenib and Trametinib Therapy in BRAF Mutation-Positive Advanced Melanoma Patients: Guidelines From Australian Melanoma Medical Oncologists

Asia-Pacific Journal of Clinical Oncology
MedicineOncology
2016English

Encorafenib/Binimetinib for the Treatment of BRAF-mutant Advanced, Unresectable, or Metastatic Melanoma: Design, Development, and Potential Place in Therapy

OncoTargets and Therapy
OncologyPharmacology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy